Clinical and bone marrow effects of α-interferon therapy in myelofibrosis with myeloid metaplasia.

被引：0
|
作者：
Tefferi, A [1 ]
Elliott, MA [1 ]
Yoon, SY [1 ]
Li, CY [1 ]
Mesa, RA [1 ]
Call, TG [1 ]
Dispenzieri, A [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3222
引用
收藏
页码：745A / 745A
页数：1
相关论文
共 50 条
  • [41] Incidence and clinical profile of JAK2 V617F mutation in myelofibrosis with myeloid metaplasia.
    Barosi, G
    Marchetti, M
    Massa, M
    Rosti, V
    Vannucchi, A
    Invernizzi, R
    Campanelli, R
    Viarengo, G
    Magrini, U
    Bergamaschi, G
    BLOOD, 2005, 106 (11) : 78A - 78A
  • [42] Antemortem presentation and management of non-hepatosplenic extramedullary hematopoiesis in myelofibrosis with myeloid metaplasia.
    Houck, WA
    Mesa, RA
    Tefferi, A
    BLOOD, 2000, 96 (11) : 747A - 747A
  • [43] Gleevec therapy in myelofibrosis with myeloid metaplasia (MMM).
    Tefferi, AW
    Mesa, RA
    Gray, LA
    Steensma, DP
    Camoriano, JK
    Elliott, MA
    Pardanani, A
    Ansell, SM
    Call, TG
    Colon-Otero, G
    Geyer, SM
    Hanson, CA
    Dewald, GW
    Kaufmann, SH
    BLOOD, 2001, 98 (11) : 626A - 626A
  • [44] Clinical and bone marrow histological correlates of peripheral blood CD34 count in myelofibrosis with myeloid metaplasia (MMM).
    Tefferi, A
    Diehn, FE
    Baek, J
    Mesa, RA
    Hoyer, JD
    BLOOD, 2001, 98 (11) : 627A - 627A
  • [45] PRIMARY MYELOFIBROSIS-OSTEOMYELOSCLEROSIS (AGNOGENIC MYELOID METAPLASIA) - CORRELATION OF CLINICAL FINDINGS WITH BONE-MARROW HISTOPATHOLOGY AND PROGNOSIS
    THIELE, J
    STEINBERG, T
    ZANKOVICH, R
    FISCHER, R
    ANTICANCER RESEARCH, 1989, 9 (02) : 429 - 435
  • [46] ALPHA-INTERFERON IN THE TREATMENT OF SYMPTOMATIC MYELOFIBROSIS WITH MYELOID METAPLASIA
    PARMEGGIANI, L
    FERRANT, A
    RODHAIN, J
    MICHAUX, JL
    SOKAL, G
    EUROPEAN JOURNAL OF HAEMATOLOGY, 1987, 39 (03) : 228 - 232
  • [47] Allogeneic blood cell transplantation following reduced intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia.
    Devine, SM
    Verma, A
    Shah, R
    Bradlow, BA
    Maynard, V
    Jessop, E
    Peace, D
    Huml, M
    Thomason, D
    Chen, YH
    Hoffman, R
    BLOOD, 2001, 98 (11) : 626A - 626A
  • [48] Comparison of peripheral blood interphase cytogenetics with bone marrow karyotype analysis in myelofibrosis with myeloid metaplasia
    Tefferi, A
    Meyer, RG
    Wyatt, WA
    Dewald, GW
    BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (02) : 316 - 319
  • [49] ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR POSTPOLYCYTHEMIC MYELOID METAPLASIA WITH MYELOFIBROSIS - A CASE-REPORT
    DEREVEL, T
    GIRAUDIER, S
    NEDELLEC, G
    JOUSSEMET, M
    BOURIN, P
    SCHILL, H
    GAILLARD, JF
    AUZANNEAU, G
    BONE MARROW TRANSPLANTATION, 1995, 16 (01) : 187 - 189
  • [50] CYTOGENETIC STUDIES OF BONE-MARROW FIBROBLASTS CULTURED FROM PATIENTS WITH MYELOFIBROSIS AND MYELOID METAPLASIA
    WANG, JC
    LANG, HD
    LICHTER, S
    WEINSTEIN, M
    BENN, P
    BRITISH JOURNAL OF HAEMATOLOGY, 1992, 80 (02) : 184 - 188
12345